Prognostic significance of 5T4 oncofetal antigen expression in colorectal carcinoma.
about
Glycosylation and epitope mapping of the 5T4 glycoprotein oncofoetal antigenPhase I dose escalation, pharmacokinetic and pharmacodynamic study of naptumomab estafenatox alone in patients with advanced cancer and with docetaxel in patients with advanced non-small-cell lung cancerStructural Insights into the Inhibition of Wnt Signaling by Cancer Antigen 5T4/Wnt-Activated Inhibitory Factor 1Embryonic expression of murine 5T4 oncofoetal antigen is associated with morphogenetic events at implantation and in developing epitheliaCD4+CD25+FOXP3+ regulatory T cells suppress anti-tumor immune responses in patients with colorectal cancer.First-in-human trial of an anti-5T4 antibody-monomethylauristatin conjugate, PF-06263507, in patients with advanced solid tumors.CXCR4 mediated chemotaxis is regulated by 5T4 oncofetal glycoprotein in mouse embryonic cells.Evaluation of MVA-5T4 as a novel immunotherapeutic vaccine in colorectal, renal and prostate cancer.Metastasis-associated 5T4 antigen disrupts cell-cell contacts and induces cellular motility in epithelial cells.Loss of function of e-cadherin in embryonic stem cells and the relevance to models of tumorigenesisCD8 T-cell recognition of human 5T4 oncofetal antigen.Control of established colon cancer xenografts using a novel humanized single chain antibody-streptococcal superantigen fusion protein targeting the 5T4 oncofetal antigen.A Novel Strategy for Detection and Enumeration of Circulating Rare Cell Populations in Metastatic Cancer Patients Using Automated Microfluidic Filtration and Multiplex Immunoassay.T-cell libraries allow simple parallel generation of multiple peptide-specific human T-cell clones.E-cadherin inhibits cell surface localization of the pro-migratory 5T4 oncofetal antigen in mouse embryonic stem cellsExpression of the 5T4 oncofoetal antigen in renal cell carcinoma: a potential target for T-cell-based immunotherapy.Therapy of human non-small-cell lung carcinoma using antibody targeting of a modified superantigen.Secreted and transmembrane wnt inhibitors and activators.5T4-modified vaccinia ankara: progress in tumor-associated antigen-based immunotherapy.Phase II trial of Modified Vaccinia Ankara (MVA) virus expressing 5T4 and high dose Interleukin-2 (IL-2) in patients with metastatic renal cell carcinoma.Vaccine therapy for renal cancer.Marine Antibody-Drug Conjugates: Design Strategies and Research Progress.5T4-modified vaccinia Ankara: progress in tumor-associated antigen-based immunotherapy.Identification of Pre- and Post-Treatment Markers, Clinical, and Laboratory Parameters Associated with Outcome in Renal Cancer Patients Treated with MVA-5T4.Naptumomab estafenatox: targeted immunotherapy with a novel immunotoxinCancer vaccines in colon and rectal cancer over the last decade: lessons learned and future directions.Evolving Strategies for Target Selection for Antibody-Drug Conjugates.5T4 oncofoetal antigen: an attractive target for immune intervention in cancer.MVA-5T4-induced immune responses are an early marker of efficacy in renal cancer patients.5T4 oncofoetal glycoprotein: an old target for a novel prostate cancer immunotherapy.Clinical Efficacy of TroVax in the Treatment of Progressive Castration-resistant Prostate Cancer.Targeting immune effector molecules to human tumor cells through genetic delivery of 5T4-specific scFv fusion proteins.Characterization of the murine 5T4 oncofoetal antigen: a target for immunotherapy in cancer.The function of e-cadherin in stem cell pluripotency and self-renewalVaccination of castration-resistant prostate cancer patients with TroVax (MVA-5T4) in combination with docetaxel: a randomized phase II trial.Vaccination of colorectal cancer patients with TroVax given alongside chemotherapy (5-fluorouracil, leukovorin and irinotecan) is safe and induces potent immune responses.Regulation of autologous immunity to the mouse 5T4 oncofoetal antigen: implications for immunotherapy.Active treatment of murine tumors with a highly attenuated vaccinia virus expressing the tumor associated antigen 5T4 (TroVax) is CD4+ T cell dependent and antibody mediated.Enrichment and Detection of Circulating Tumor Cells and Other Rare Cell Populations by Microfluidic Filtration.Analysis of pre-treatment markers predictive of treatment benefit for the therapeutic cancer vaccine MVA-5T4 (TroVax).
P2860
Q24534036-225D53FD-2D29-4E63-B486-4D24E40EAE08Q24645548-93E3E320-7701-452B-9572-95D7004A3552Q27681929-66C5CED6-BD6D-4F1B-A52A-45ECCCD7EEC8Q28513567-6480792B-5DB1-4363-BFF3-0844A6275F2CQ33268298-8B8148BD-82FE-49C1-B8DA-80FFFDEBE621Q33438286-607AFF64-5FD2-4C8A-881B-ED3417C9C2C7Q33550832-6DC30F24-74E6-4537-8D78-113C9533B91DQ34260594-3D4F4645-C124-4C1E-9FFA-440CEEA4CB6AQ34405136-2937B10D-E0E5-4834-822F-41C27C7DC9F7Q34423998-56AA9B52-C183-4CF0-A034-57BE0FA99C18Q34518944-C6E95934-232B-4A9E-8281-038B0A9150A4Q35149457-70C106D8-4E19-405B-8312-96A207DC44ECQ35818839-DC81D25E-449E-46EE-AFDE-132418D5F391Q35908845-5B82FF34-A8B6-4200-862C-CD7C355A0214Q35942348-1EFEE129-E64F-4C44-B62F-76B68CB83942Q36615307-88D78A3C-66EF-404A-B51A-89146A5B4595Q36623092-2CB72761-3831-4B23-A50F-7DDFBEFDFB1DQ36626700-68298934-B90E-4C5A-ADEC-E1B2F873642BQ36922276-C25EB8B9-844E-4E2C-932B-A9E2B76F8FBEQ37074226-FD8368C6-463E-4DC6-AC79-A1C22AF4DA1EQ37259586-0439B15A-F752-471F-8B66-9A637779007AQ37628646-9169A1D5-D5E6-4114-B3AF-63B65F3D2A14Q37678414-F8EE31E0-37A9-4F37-B1F7-BB227F2D41E5Q38123176-55A59799-E3FC-4569-BE4E-B4EF7A0ECB05Q38180315-38AAC256-6810-4F23-A1C3-51A3D8A48040Q38828624-EB96FC17-FB3A-464F-9C6C-63F5F6C336C5Q38920359-DF4160E7-FA10-4A2E-8DD7-2DB0628B2C20Q38984929-34EC79C4-500E-421A-BB2A-7494CF767361Q39774023-4652D9B5-2DD2-4D11-A8CD-E176439F0DB0Q40188258-A7E04A5C-909C-4FBE-9D69-5CBD42423F84Q40357390-DB6682FD-1E2E-433D-BF59-B378F8E64EA2Q40696514-5810DE04-60F2-4EF7-91C2-4942249F70A5Q40732932-A34A4B81-F4AE-4F31-977B-FF2F015B999EQ41956122-D4E5F821-C971-4B4B-A253-BF17E2C5AE23Q42282117-A25730FF-3060-4918-88EC-6EA3FF6EB02DQ42638914-2F11FF74-6EB5-4BE6-895E-234A051A717AQ45025116-0F97572C-00E1-4B3B-841A-50F9B3A5EA6BQ45422169-6EAB1810-7B19-490C-9645-95797FBC9771Q46130140-D589A1F6-DC42-4004-9778-220890324D60Q47630188-484AD123-2394-4E9B-BD67-4E93AA6C5535
P2860
Prognostic significance of 5T4 oncofetal antigen expression in colorectal carcinoma.
description
1994 nî lūn-bûn
@nan
1994年の論文
@ja
1994年論文
@yue
1994年論文
@zh-hant
1994年論文
@zh-hk
1994年論文
@zh-mo
1994年論文
@zh-tw
1994年论文
@wuu
1994年论文
@zh
1994年论文
@zh-cn
name
Prognostic significance of 5T4 oncofetal antigen expression in colorectal carcinoma.
@ast
Prognostic significance of 5T4 oncofetal antigen expression in colorectal carcinoma.
@en
type
label
Prognostic significance of 5T4 oncofetal antigen expression in colorectal carcinoma.
@ast
Prognostic significance of 5T4 oncofetal antigen expression in colorectal carcinoma.
@en
prefLabel
Prognostic significance of 5T4 oncofetal antigen expression in colorectal carcinoma.
@ast
Prognostic significance of 5T4 oncofetal antigen expression in colorectal carcinoma.
@en
P2093
P2860
P356
P1476
Prognostic significance of 5T4 oncofetal antigen expression in colorectal carcinoma.
@en
P2093
P2860
P2888
P304
P356
10.1038/BJC.1994.173
P407
P577
1994-05-01T00:00:00Z
P5875
P6179
1029959667